Compare GPCR & EXPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GPCR | EXPO |
|---|---|---|
| Founded | 2016 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Professional Services |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.4B |
| IPO Year | 2023 | 1996 |
| Metric | GPCR | EXPO |
|---|---|---|
| Price | $55.25 | $67.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $103.36 | $88.00 |
| AVG Volume (30 Days) | ★ 1.1M | 433.8K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.86% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $582,014,000.00 |
| Revenue This Year | N/A | $12.75 |
| Revenue Next Year | N/A | $8.50 |
| P/E Ratio | ★ N/A | $32.19 |
| Revenue Growth | N/A | ★ 4.21 |
| 52 Week Low | $15.80 | $63.25 |
| 52 Week High | $94.90 | $83.92 |
| Indicator | GPCR | EXPO |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 52.60 |
| Support Level | $17.89 | $64.33 |
| Resistance Level | $61.20 | $70.52 |
| Average True Range (ATR) | 3.42 | 2.02 |
| MACD | 1.44 | 0.40 |
| Stochastic Oscillator | 86.18 | 96.29 |
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.